Statistical simulation using data from the foundation for the national institute of health/osteoarthritis initiative biomarkers consortium to evaluate the clinical utility of prognostic knee osteoarthritis biomarkers in designing a knee osteoarthritis clinical trial S. Feng, Z. Liu, F. Hong, J. Medema, R. Kamath, M. Levesque Osteoarthritis and Cartilage Volume 25, Pages S34-S35 (April 2017) DOI: 10.1016/j.joca.2017.02.069 Copyright © 2017 Terms and Conditions
Fig. 1 Potential benefit* and eost† of using urine CTX-II, MRI/BML, or no biomarker (reference) in a future knee OΛ trial. BML, bone marrow lesion; CTX-II, C-telopeptide of type 2 collagen; MRI, magnetic resonance imaging; OA, osteoarthritis. *Enrichment of progressers. †Size of subgroup or screen failure rate. Osteoarthritis and Cartilage 2017 25, S34-S35DOI: (10.1016/j.joca.2017.02.069) Copyright © 2017 Terms and Conditions